Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.56 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | TYR | P14679 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132920 | 0.83 | ALOX15 (0.59) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL8657615 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL9244593 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL30449795 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL1882430 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL11443426 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL8656911 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL8659595 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL11438035 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT | |
| SCHEMBL23409677 | 0.79 | ALOX15 (0.54) | SMN1; SMN2ALDH1A1ALOX15CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2617418-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20160244392-A1 | SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160244392-A1 | SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2016-08-25 | — | — | US | disclosed |
| US-9278085-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278085-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2617418-A1 | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2617417-A1 | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1986636-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2332534-A1 | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1933821-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | Edison Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007100652-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244392-A1 | SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | FH, NDUFAB1, ACAA2 | SMN1; SMN2 299/4885ALDH1A1 406/4885ALOX15 420/4885 |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ACAA2 | SMN1; SMN2 299/4885ALDH1A1 406/4885ALOX15 420/4885 |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ECHS1 | SMN1; SMN2 216/4885ALDH1A1 465/4885ALOX15 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.